Where does Oncomed Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Oncomed Pharmaceuticals, Inc. ranks #5,782 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Oncomed Pharmaceuticals, Inc. hold?

Oncomed Pharmaceuticals, Inc. holds 59 US utility patents granted between 2015 and 2021, spanning 10 technology areas.

What is Oncomed Pharmaceuticals, Inc.'s Innovation Score?

Oncomed Pharmaceuticals, Inc. has an Innovation Score of 37.5 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Oncomed Pharmaceuticals, Inc. focus on?

Oncomed Pharmaceuticals, Inc.'s top technology area is C07K (Peptides) with 59 patents, ranking #145 of 3,615 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Oncomed Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Oncomed Pharmaceuticals, Inc.'s recent grant velocity is -93% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Oncomed Pharmaceuticals, Inc.'s patents?

Oncomed Pharmaceuticals, Inc.'s patents average 20.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Oncomed Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Oncomed Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 59 granted patents across 10 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Oncomed ranks #5,782 of 49,997 tracked US assignees by granted-patent volume, with 59 patents across 10 technology areas.

#5,782
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.5/100): 20.2
avg claims per patent: -93%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5782 · US Corporation #5,782 · 59 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 59 grants
UPPER-Q #5,782/49,997
PHOTO-FINISH Mahle Metal Leve S/A
CPC-FOCUS C07K · 10 areas
INNOV-THIN 37.5/100
CLAIMS-DENSE 20.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -93% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mahle Metal Leve S/A (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Oncomed’s 37.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.1 pts (38%) Velocity 0.0 pts (0%) Breadth 11.2 pts (30%) Claim depth 12.1 pts (32%)

Qualcomm Incorporated · highest

85
Aehr Test Systems · near

37
Nationwide Mutual… · near

37
Mullet Tools · near

37
Oncomed Pharmaceutic… · this assignee

37
SeaSpine · near

37
3D Lighting… · lowest

7

What this shows Oncomed's Innovation Score is 37.5/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Oncomed?

Each dot is one of Oncomed’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oncomed’s own 20.2 claims/patent is ABOVE the 10.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Oncomed vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Oncomed's grants concentrate

Oncomed Pharmaceuticals, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (17 grants) versus a trough of 1 in 2019. By volume, Oncomed sits between Mahle Metal Leve S/A and Pum-tech Korea Co., Ltd.

Mahle Metal Leve…

59
Microfabrica

59
NR Engineering

59
Nomura Research I…

59
Orion

59
Orvance

59
Otsuka Pharmaceut…

59
Pum-tech Korea

59
Oncomed Pharmaceu… ◀

59

What this shows Oncomed holds 59 patents at rank #5,782, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Oncomed

By rank, the assignees closest to #5,782 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Oncomed's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Oncomed, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Oncomed ranks #145 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (37 here).

SeaSpine, Inc. 37 Mullet Tools, LLC 37 Nationwide Mutual Insurance Company 37 Aehr Test Systems 37

Similar claim depth

Nearest assignees by average claims per patent (20.2 here).

Sony Network Entertainment International LLC 20.2 avg Intellectual Ventures II LLC 20.2 avg Accenture Global Services Limited 20.2 avg Mobile Technology Corporation 20.2 avg

Oncomed's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Oncomed Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	17	28.8%
2016	16	27.1%
2017	14	23.7%
2018	7	11.9%
2019	1	1.7%
2020	3	5.1%
2021	1	1.7%

Which technologies does Oncomed Pharmaceuticals, Inc. patent most?

C07K - Peptides 59

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 54

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 53

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 17

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 17

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

Y02A - Technologies FOR Adaptation TO Climate Change 4

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 4

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Oncomed Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Oncomed Pharmaceuticals, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #5,782 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Oncomed Pharmaceuticals, Inc. against Mahle Metal Leve S/A, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.